文献速递甲状腺与颈部外科

人类与人工智能在分化型甲状腺癌放射性碘治疗决策中的对比:一项概念验证研究

Human versus artificial intelligence decision-making for radioactive iodine use in differentiated thyroid cancer-A proof of concept.
PubMed 文献 · Surgery · 2026-09-02

本研究回顾性提取100例成人分化型甲状腺癌全甲状腺切除术患者资料,基于文献构建各ATA风险分层的共识参考放射性碘使用率,并比较医生处方与四个AI平台的推荐。结果显示不同AI平台推荐存在差异,部分平台与医生推荐均偏离共识估计,但AI可能辅助人类决策以贴近指南。

要点

  • AI平台在放射性碘推荐上表现不一,未专门训练时差异明显。
  • 低危患者中医生和Gemini推荐率高于共识估计的10%。
  • 中危患者中医生和Doximity GPT推荐率高于共识估计的50%。

核心结论

  • 未专门针对分化型甲状腺癌训练的大语言模型在推荐放射性碘治疗时存在变异性,但可能补充人类推荐并促进与共识指南的一致性。

研究设计与样本

  • 回顾性提取100例成人分化型甲状腺癌全甲状腺切除术患者的人口学、手术和病理资料,并通过文献综述构建基于2015 ATA风险分层的共识参考放射性碘使用率。
  • 查询四个AI平台对每例患者术后放射性碘使用给出推荐,将医生处方与AI推荐分别与共识估计率进行二项精确检验比较。

主要发现

  • 100例患者中位年龄48岁,81%为女性;2015 ATA风险分层为低危59例、中危25例、高危16例。
  • 低危患者中,医生和Google Gemini推荐放射性碘的比例分别为24%和19%,均显著高于共识估计的10%。
  • 中危患者中,医生(92%)和Doximity GPT(76%)推荐率均超过共识估计的50%。
  • 高危患者中,Open Evidence推荐放射性碘的比例为69%,显著低于所有比较对象。

临床怎么用

  • AI平台可作为辅助工具,帮助临床医生在分化型甲状腺癌术后放射性碘决策中对照共识指南,但需注意平台间差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The decision to administer postoperative radioactive iodine therapy in differentiated thyroid cancer is evolving. Given the growing utility of large language models in medical decision-making, we hypothesize that artificial intelligence models can inform recommendations regarding postoperative radioactive iodine therapy. METHODS: After institutional review board approval, demographic, operative, and pathologic details from 100 adult patients with differentiated thyroid cancer who underwent total thyroidectomy were retrospectively extracted. A comprehensive literature review was conducted to model an appropriate radioactive iodine consensus-informed estimate for each American Thyroid Association risk category. Four artificial intelligence platforms were queried for recommendations on the utility of postoperative radioactive iodine for each patient. The physician prescribed radioactive iodine treatment (human recommendation) and results of the artificial intelligence queries (artificial intelligence recommendation) were compared with the estimated radioactive iodine rates using binomial exact tests. RESULTS: Of the 100 patients reviewed, the median age was 48 years, and 81% were female. The 2015 American Thyroid Association risk stratification resulted in 59 low-, 25 intermediate-, and 16 high-risk patients. Physicians and Google Gemini recommended radioactive iodine in 24% and 19% of low-risk patients, respectively, which was statistically greater than the consensus-informed estimate of 10%. In intermediate-risk patients, both physicians (92%) and Doximity GPT (76%) exceeded the radioactive iodine consensus-informed estimate of 50%. In high-risk patients, Open Evidence recommended radioactive iodine at a significantly lower rate (69%) than all comparators. CONCLUSION: Large language models that are not specifically trained for differentiated thyroid cancer management demonstrate variability in recommending radioactive iodine therapy. However, these platforms may complement human recommendations for radioactive iodine administration, with promise toward aligning radioactive iodine use with consensus guidelines.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Robson Chase ME, Hubbuch J, McMullen CA, et al. Human versus artificial intelligence decision-making for radioactive iodine use in differentiated thyroid cancer-A proof of concept. Surgery. 2026. PMID: 42791092. doi:10.1016/j.surg.2026.110590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。